SG11201506413PA - Sequestrants of advanced glycation end product (age) precursors - Google Patents

Sequestrants of advanced glycation end product (age) precursors

Info

Publication number
SG11201506413PA
SG11201506413PA SG11201506413PA SG11201506413PA SG11201506413PA SG 11201506413P A SG11201506413P A SG 11201506413PA SG 11201506413P A SG11201506413P A SG 11201506413PA SG 11201506413P A SG11201506413P A SG 11201506413PA SG 11201506413P A SG11201506413P A SG 11201506413PA
Authority
SG
Singapore
Prior art keywords
sequestrants
precursors
age
end product
advanced glycation
Prior art date
Application number
SG11201506413PA
Inventor
Stephen Randall Holmes-Farley
Pradeep Dhal
Magnus Besev
Robert J Miller
Andrew T Papoulis
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of SG11201506413PA publication Critical patent/SG11201506413PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F126/00—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen
    • C08F126/02—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen by a single or double bond to nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Polymers & Plastics (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
SG11201506413PA 2013-03-15 2014-03-12 Sequestrants of advanced glycation end product (age) precursors SG11201506413PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361792719P 2013-03-15 2013-03-15
PCT/US2014/024436 WO2014150873A1 (en) 2013-03-15 2014-03-12 Sequestrants of advanced glycation end product (age) precursors

Publications (1)

Publication Number Publication Date
SG11201506413PA true SG11201506413PA (en) 2015-09-29

Family

ID=50439508

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201506413PA SG11201506413PA (en) 2013-03-15 2014-03-12 Sequestrants of advanced glycation end product (age) precursors
SG10201707590XA SG10201707590XA (en) 2013-03-15 2014-03-12 Sequestrants of advanced glycation end product (age) precursors

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201707590XA SG10201707590XA (en) 2013-03-15 2014-03-12 Sequestrants of advanced glycation end product (age) precursors

Country Status (24)

Country Link
US (2) US20160024233A1 (en)
EP (1) EP2968403A1 (en)
JP (4) JP2016512830A (en)
KR (1) KR20150130492A (en)
CN (1) CN105188718A (en)
AR (1) AR095593A1 (en)
AU (2) AU2014235500A1 (en)
BR (1) BR112015023404A8 (en)
CA (1) CA2906501A1 (en)
CL (1) CL2015002624A1 (en)
CR (1) CR20150545A (en)
DO (1) DOP2015000221A (en)
EA (1) EA201591733A1 (en)
HK (1) HK1220607A1 (en)
IL (1) IL241406A0 (en)
MA (1) MA38487A1 (en)
MX (1) MX2015012843A (en)
PE (1) PE20151766A1 (en)
PH (1) PH12015502019A1 (en)
SG (2) SG11201506413PA (en)
TN (1) TN2015000390A1 (en)
TW (1) TW201521744A (en)
UY (1) UY35441A (en)
WO (1) WO2014150873A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41202A (en) * 2014-12-18 2017-10-24 Genzyme Corp CROSS-LINKED POLYDIALLYMINE COPOLYMERS FOR THE TREATMENT OF TYPE 2 DIABETES
CN111405870A (en) * 2017-08-31 2020-07-10 西托索尔本茨公司 Reduction of advanced glycation end products from body fluids

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985938A (en) * 1997-11-05 1999-11-16 Geltex Pharmaceuticals, Inc. Method for reducing oxalate
WO2002085377A1 (en) * 2001-04-18 2002-10-31 Genzyme Corporation Method for lowering serum glucose
AU2003263010A1 (en) * 2003-09-02 2005-04-21 Genzyme Corporation Method for reducing vascular inflammation
US7385012B2 (en) * 2003-11-03 2008-06-10 Ilypsa, Inc. Polyamine polymers
US7459502B2 (en) * 2003-11-03 2008-12-02 Ilypsa, Inc. Pharmaceutical compositions comprising crosslinked polyamine polymers
WO2005079463A2 (en) * 2004-02-17 2005-09-01 Dynamis Therapeutics, Inc. Fructoseamine 3 kinase and the formation of collagen and elastin
FR2883873B1 (en) * 2005-03-31 2009-07-10 Pharmamens Sarl AGE INHIBITORS
CA2790999C (en) * 2010-02-24 2019-05-14 Relypsa, Inc. Crosslinked polyvinylamine, polyallylamine, and polyethyleneimine for use as bile acid sequestrants

Also Published As

Publication number Publication date
CR20150545A (en) 2015-12-01
PE20151766A1 (en) 2015-12-11
TW201521744A (en) 2015-06-16
BR112015023404A2 (en) 2017-07-18
EA201591733A1 (en) 2016-01-29
JP2020055850A (en) 2020-04-09
EP2968403A1 (en) 2016-01-20
US20160024233A1 (en) 2016-01-28
MX2015012843A (en) 2016-08-08
SG10201707590XA (en) 2017-11-29
JP2022037143A (en) 2022-03-08
AU2019201259A1 (en) 2019-03-14
MA38487A1 (en) 2017-12-29
BR112015023404A8 (en) 2019-12-03
AR095593A1 (en) 2015-10-28
WO2014150873A1 (en) 2014-09-25
TN2015000390A1 (en) 2017-01-03
UY35441A (en) 2014-10-31
PH12015502019A1 (en) 2016-01-11
CA2906501A1 (en) 2014-09-25
CL2015002624A1 (en) 2016-03-11
HK1220607A1 (en) 2017-05-12
KR20150130492A (en) 2015-11-23
US20180265613A1 (en) 2018-09-20
AU2014235500A1 (en) 2015-11-05
CN105188718A (en) 2015-12-23
DOP2015000221A (en) 2015-12-15
JP2016512830A (en) 2016-05-09
IL241406A0 (en) 2015-11-30
JP2018135365A (en) 2018-08-30

Similar Documents

Publication Publication Date Title
GB201317887D0 (en) Product
GB201312991D0 (en) Process
SG11201508447TA (en) Expression process
GB201307334D0 (en) Process
GB2511521B (en) Product presenter
GB2512902B (en) Oligomerisation Process
GB201316269D0 (en) Process
GB201313915D0 (en) Process
GB201312729D0 (en) Cleaning product
GB2512903B (en) Oligomerisation Process
GB201314334D0 (en) Process
GB201302441D0 (en) Process
HK1220607A1 (en) Sequestrants of advanced glycation end product (age) precursors (age)
IL239449A0 (en) Process
GB201415000D0 (en) Improved process
GB201311769D0 (en) Product
GB201302290D0 (en) Cleaning product
GB201307327D0 (en) Process
GB2518955B (en) Comestible product
GB201413623D0 (en) Process
GB201307951D0 (en) Process
GB201316253D0 (en) Process
GB201306308D0 (en) Novel process
GB201402500D0 (en) Product
GB201314573D0 (en) Product